Dr Reddy's Laboratories Cash on Hand 2010-2024 | RDY

Dr Reddy's Laboratories cash on hand from 2010 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • Dr Reddy's Laboratories cash on hand for the quarter ending June 30, 2024 was $1.141B, a 50.93% increase year-over-year.
  • Dr Reddy's Laboratories cash on hand for 2024 was $0.979B, a 27.64% increase from 2023.
  • Dr Reddy's Laboratories cash on hand for 2023 was $0.767B, a 25.74% increase from 2022.
  • Dr Reddy's Laboratories cash on hand for 2022 was $0.61B, a 24.49% increase from 2021.
Dr Reddy's Laboratories Annual Cash on Hand
(Millions of US $)
2024 $979
2023 $767
2022 $610
2021 $490
2020 $356
2019 $363
2018 $325
2017 $284
2016 $606
2015 $650
2014 $568
2013 $415
2012 $357
2011 $130
2010 $226
2009 $
Dr Reddy's Laboratories Quarterly Cash on Hand
(Millions of US $)
2024-06-30 $1,141
2024-03-31 $979
2023-12-31 $877
2023-09-30 $827
2023-06-30 $756
2023-03-31 $767
2022-12-31 $589
2022-09-30 $346
2022-06-30 $439
2022-03-31 $610
2021-12-31 $497
2021-09-30 $347
2021-06-30 $394
2021-03-31 $490
2020-12-31 $243
2020-09-30 $354
2020-06-30 $371
2020-03-31 $356
2019-12-31 $286
2019-09-30 $411
2019-06-30 $392
2019-03-31 $363
2018-12-31 $365
2018-09-30 $272
2018-06-30 $232
2018-03-31 $325
2017-12-31 $350
2017-09-30 $260
2017-06-30 $231
2017-03-31 $284
2016-12-31 $298
2016-09-30 $323
2016-06-30 $380
2016-03-31 $606
2015-12-31 $577
2015-09-30 $523
2015-06-30 $561
2015-03-31 $650
2014-12-31 $118
2014-09-30 $471
2014-06-30 $548
2014-03-31 $568
2013-12-31 $507
2013-09-30 $442
2013-06-30 $505
2013-03-31 $415
2012-12-31 $435
2012-09-30 $410
2012-06-30 $384
2012-03-31 $357
2011-12-31 $349
2011-09-30 $192
2011-06-30 $125
2011-03-31 $130
2010-12-31 $99
2010-09-30 $134
2010-06-30 $188
2010-03-31 $226
2009-12-31 $157
2009-09-30 $128
2009-06-30 $139
2009-03-31 $120
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $12.399B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00